A MDVN investor filed a lawsuit on behalf of purchasers of Medivation, Inc. (NASDAQ:MDVN) common stock during the period between July 17, 2008 and March 2, 2010, against Medivation, Inc. Meanwhile an investigation on behalf of current long term investors in Medivation, Inc. (NASDAQ:MDVN) was announced.
If you are a current long term investor in Medivation, Inc. (NASDAQ:MDVN) common stock, you have certain options and you should contact the Shareholders Foundation, Inc. by email at: mail@shareholdersfoundation.com or at: +1 (858) 779 – 1554
Medivation, Inc., located in San Francisco, California, is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer’s disease, Huntington’s disease and castration-resistant prostate cancer. According to the complaint filed in in the United States District Court for the Northern District of California the plaintiff alleges that Medivation, Inc. and certain of its officers and directors violated the Securities Exchange Act of 1934 by issuing between July 17, 2008 and March 2, 2010 false and misleading statements regarding its drug Dimebon. Then, on March 3, 2010, before the market opened, defendants were forced to publicly disclose that Dimebon did not meet primary and secondary goals in a Phase 3 trial for patients with mild to moderate Alzheimer’s disease, and as a result of this news, Medivation’s stock plummeted $27.15 per share to close at $13.10 per share on March 3, 2010 – a one-day decline of 67%, so the lawsuit. Shares of Medivation, Inc. (NASDAQ:MDVN) continued to decline from its 52weekHigh of $40.49 per share to $12.10 per share on Tuesday, March 09, 2010.
Those who are current long term investors in Medivation, Inc. (NASDAQ:MDVN) common stock, have certain options and should contact the Shareholders Foundation, Inc. by email at: mail@shareholdersfoundation.com or at: +1 (858) 779 – 1554
Source: http://www.prlog.org/10586773-medivation-inc-long-term-shareholder-investigation.html
No comments:
Post a Comment